Impact of oral cyclophosphamide on health-related quality of life in patients with active scleroderma lung disease: Results from the scleroderma lung study

Arthritis and Rheumatism

Volumn 56, Issue 5, 2007, Pages 1676-1684

  Khanna, Dinesh ^a,o   Yan, Xiaohong ^b   Tashkin, Donald P ^b   Furst, Daniel E ^b   Elashoff, Robert ^b   Roth, Michael D ^b   Silver, Richard ^c   Strange, Charlie ^c   Bolster, Marcy ^c   Seibold, James R ^d   Riley, David J ^e   Hsu, Vivien M ^e   Varga, John ^f   Schraufnagel, Dean E ^f   Theodore, Arthur ^g   Simms, Robert ^g   Wise, Robert ^h   Wigley, Fredrick ^h   White, Barbara ^h   Steen, Virginia ⁱ   Read, Charles ⁱ   Mayes, Maureen ^j   Parsley, Ed ^j   Mubarak, Kamal ^k   Connolly, M Kari ^l   Golden, Jeffrey ^l   Olman, Mitchell ^m   Fessler, Barri ^m   Rothfield, Naomi ⁿ   Metersky, Mark ⁿ   Clements, Philip J ^b   more..

^a UNIVERSITY OF CINCINNATI   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^d UNIVERSITY OF MICHIGAN   (United States)

^e ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^f UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^g BOSTON UNIVERSITY   (United States)

^h JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁱ GEORGETOWN UNIVERSITY   (United States)

^j UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^k WAYNE STATE UNIVERSITY   (United States)

^l UNIVERSITY OF CALIFORNIA   (United States)

^m UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

ⁿ UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

^o UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; PLACEBO;

ADULT; ARTICLE; CONTROLLED STUDY; FEMALE; GENERAL HEALTH QUESTIONNAIRE; HEALTH ASSESSMENT QUESTIONNAIRE; HEALTH STATUS; HUMAN; LUNG DISEASE; MAJOR CLINICAL STUDY; MALE; MENTAL HEALTH; PRIORITY JOURNAL; QUALITY OF LIFE; SCLERODERMA; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME;

ADULT; ANTIRHEUMATIC AGENTS; CYCLOPHOSPHAMIDE; DISABILITY EVALUATION; DOUBLE-BLIND METHOD; FEMALE; HEALTH STATUS INDICATORS; HUMANS; LONGITUDINAL STUDIES; LUNG DISEASES; MALE; MIDDLE AGED; QUALITY OF LIFE; REPRODUCIBILITY OF RESULTS; SCLERODERMA, SYSTEMIC; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 34248589179     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.22580     Document Type: Article

References (52)

1. Tashkin DP, Elashoff R, Clements PJ, Goldin J, Roth MD, Furst DE, et al. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 2006;354:2655-66.
2. Khanna D, Clements PJ, Furst DE, Chon Y, Elashoff R, Roth MD, et al, for the Scleroderma Lung Study Group. Correlation of the degree of dyspnea with health-related quality of life, functional abilities, and diffusing capacity for carbon monoxide in patients with systemic sclerosis and active alveolitis: results from the Scleroderma Lung Study. Arthritis Rheum 2005;52:592-600.
3. Tsevat J, Weeks JC, Guadagnoli E, Tosteson AN, Mangione CM, Pliskin JS, et al. Using health-related quality-of-life information: clinical encounters, clinical trials, and health policy. J Gen Intern Med 1994;9:576-82.
4. Khanna D. Health-related quality of life: a primer with focus on scleroderma. Scleroderma Care Res [article online]. 2006;3:3-13. URL: www.sctc-online.org/pdfs/SCARV3N2.pdf.
5. Tsevat J. What do utilities measure? Med Care 2000;38 Suppl 9:II160-4.
6. Khanna D, Ahmed M, Furst DE, Ginsburg SS, Park GS, Hornung R, et al. Health values of patients with systemic sclerosis. Arthritis Rheum 2007;57:86-93.
7. Kopec JA, Willison KD. A comparative review of four preference-weighted measures of health-related quality of life [review]. J Clin Epidemiol 2003;56:317-25.
8. Brazier J, Usherwood T, Harper R, Thomas K. Deriving a preference-based single index from the UK SF-36 health survey. J Clin Epidemiol 1998;51:1115-28.
9. Jaeschke R, Singer J, Guyatt GH. Measurement of health status: ascertaining the minimal clinically important difference. Control Clin Trials 1989;10:407-15.
10. Khanna D, Furst DE, Hays RD, Park GS, Wong WK, Seibold JR, et al. Minimally important difference in diffuse systemic sclerosis: results from the D-penicillamine study. Ann Rheum Dis 2006;65: 1325-9.
11. Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980;23:581-90.
12. Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992;30:473-83.
13. Ware JE Jr, Kosinki M, Keller S. SF-36 physical and mental health summary scales: a user's manual. Boston: The Health Institute, New England Medical Center; 1994.
14. Ware J, Kosinski M, Dewey J. How to score version two of the SF-36 health survey. Lincoln (RI): QualityMetric; 2000.
15. Kosinski M, Zhao SZ, Dedhiya S, Osterhaus JT, Ware JE Jr. Determining minimally important changes in generic and disease-specific health-related quality of life questionnaires in clinical trials of rheumatoid arthritis. Arthritis Rheum 2000;43:1478-87.
16. Angst F, Aeschlimann A, Stucki G. Smallest detectable and minimal clinically important differences of rehabilitation intervention with their implications for required sample sizes using WOMAC and SF-36 quality of life measurement instruments in patients with osteoarthritis of the lower extremities. Arthritis Rheum 2001;45:384-91.
17. Strand V, Crawford B. Improvement in the health-related quality of life in patients with SLE following sustained reductions in anti-DNA antibodies. Expert Rev Pharmacoecon Outcomes Res 2005;5:317-26.
18. Fries JF, Spitz P, Kraines RG, Holman HR. Measurement of patient outcome in arthritis. Arthritis Rheum 1980;23:137-45.
19. Clements PJ, Wong WK, Hurwitz EL, Furst DE, Mayes M, White B, et al. Correlates of the disability index of the Health Assessment Questionnaire: a measure of functional impairment in systemic sclerosis. Arthritis Rheum 1999;42:2372-80.
20. Khanna D, Furst DE, Clements PJ, Park GS, Hays RD, Yoon J, et al. Responsiveness of the SF-36 and the Health Assessment Questionnaire disability index in a systemic sclerosis clinical trial. J Rheumatol 2005;32:832-40.
21. Wells GA, Tugwell P, Kraag GR, Baker PR, Groh J, Redelmeier DA. Minimum important difference between patients with rheumatoid arthritis: the patient's perspective. J Rheumatol 1993;20: 557-60.
22. Mahler DA, Weinberg DH, Wells CK, Feinstein AR. The measurement of dyspnea: contents, interobserver agreement, and physiologic correlates of two new clinical indexes. Chest 1984;85: 751-8.
23. Witek TJ Jr, Mahler DA. Meaningful effect size and patterns of response of the transition dyspnea index. J Clin Epidemiol 2003; 56:248-55.
24. Brazier J, Roberts J, Deverill M. The estimation of a preference-based measure of health from the SF-36. J Health Econ 2002;21: 271-92.
25. Walters SJ, Brazier JE. Comparison of the minimally important difference for two health state utility measures: EQ-5D and SF-6D [review]. Qual Life Res 2005;14:1523-32.
26. Osoba D, Bezjak A, Brundage M, Zee B, Tu D, Pater J. Analysis and interpretation of health-related quality-of-life data from clinical trials: basic approach of the National Cancer Institute of Canada Clinical Trials Group. Eur J Cancer 2005;41:280-7.
27. Hays RD, Hadorn D. Responsiveness to change: an aspect of validity, not a separate dimension. Qual Life Res 1992;1:73-5.
28. Hays RD. Reliability and validity (including responsiveness). In: Fayers P, Hays RD, editors. Assessing quality of life in clinical trials: methods and practice. 2nd ed. New York: Oxford University Press; 2005. p. 25-39.
29. Liang K, Zegar S. Longitudinal data analysis using generalized linear models. Biometrika 1986;73:13-23.
30. Laird NM, Ware JH. Random-effects models for longitudinal data. Biometrics 1982;38:963-74.
31. Franzblau A. A primer of statistics for non-statisticians. New York: Harcourt, Brace & World; 1958.
32. Crosby RD, Kolotkin RL, Williams GR. Defining clinically meaningful change in health-related quality of life. J Clin Epidemiol 2003;56:395-407.
33. Cohen J. A power primer. Psychol Bull 1992;112:155-9.
34. Wyrwich KW, Bullinger M, Aaronson N, Hays RD, Patrick DL, Symonds T. Estimating clinically significant differences in quality of life outcomes. Qual Life Res 2005;14:285-95.
35. Osoba D, Brada M, Yung WK, Prados MD. Health-related quality of life in patients with anaplastic astrocytoma during treatment with temozolomide. Eur J Cancer 2000;36:1788-95.
36. Cole JC, Motivala SJ, Khanna D, Lee JY, Paulus HE, Irwin MR. Validation of single-factor structure and scoring protocol for the Health Assessment Questionnaire-disability index. Arthritis Rheum 2005;53:536-42.
37. Cole JC, Khanna D, Clements PJ, Seibold JR, Tashkin DP, Paulus HE, et al. Single-factor scoring validation for the Health Assessment Questionnaire- disability index (HAQ-DI) in patients with systemic sclerosis and comparison with early rheumatoid arthritis patients. Qual Life Res 2006;15:1383-94.
38. Nich C, Carroll KM. Intention-to-treat meets missing data: implications of alternate strategies for analyzing clinical trials data. Drug Alcohol Depend 2002;68:121-30.
39. Jorgensen B, Tsao M. Dispersion models and longitudinal data analysis [review]. Stat Med 1999;18:2257-70.
40. Walter SD. Number needed to treat (NNT): estimation of a measure of clinical benefit. Stat Med 2001;20:3947-62.
41. Manne SL, Zautra AJ. Coping with arthritis: current status and critique [review]. Arthritis Rheum 1992;35:1273-80.
42. Guyatt GH, Feeny DH, Patrick DL. Measuring health-related quality of life [review]. Ann Intern Med 1993;118:622-9.
43. Wilson IB, Cleary PD. Linking clinical variables with health-related quality of life: a conceptual model of patient outcomes. JAMA 1995;273:59-65.
44. Gliddon AE, Dore CJ, Maddison PJ, and the QUINS Trial Study Group. Influence of clinical features on the health status of patients with limited cutaneous systemic sclerosis. Arthritis Rheum 2006;55:473-9.
45. Crosby RD, Kolotkin RL, Williams GR. Defining clinically meaningful change in health-related quality of life. J Clin Epidemiol 2003;565:395-407.
46. Sloan JA, Cella D, Hays RD. Clinical significance of patient-reported questionnaire data: another step toward consensus [editorial]. J Clin Epidemiol 2005;58:1217-9.
47. Farivar S, Liu H, Hays RD. Half standard deviation estimate of the minimally important difference in health-related quality of life scores? Expert Rev Pharmacoecon Outcomes Res 2004;4:515-23.
48. Mahler DA, Matthay RA, Snyder PE, Wells CK, Loke J. Sustained-release theophylline reduces dyspnea in nonreversible obstructive airway disease. Am Rev Respir Dis 1985;131:22-5.
49. Hay JG, Stone P, Carter J, Church S, Eyre-Brook A, Pearson MG, et al. Bronchodilator reversibility, exercise performance and breathlessness in stable chronic obstructive pulmonary disease. Eur Respir J 1992;5:659-64.
50. Bellia V, Foresi A, Bianco S, Grassi V, Olivieri D, Bensi G, et al. Efficacy and safety of oxitropium bromide, theophylline and their combination in COPD patients: a double-blind, randomized, multicentre study (BREATH Trial). Respir Med 2002;96:881-9.
51. Weinstein MC, Siegel JE, Gold MR, Kamlet M, Russell LB. Recommendations of the Panel on Cost-effectiveness in Health and Medicine [review]. JAMA 1996;276:1253-8.
52. Martinez TY, Pereira CA, dos Santos ML, Ciconelli RM, Guimaraes SM, Martinez JA. Evaluation of the short-form 36-item questionnaire to measure health-related quality of life in patients with idiopathic pulmonary fibrosis. Chest 2000;117:1627-32.